Track Liquidia Corporation — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Liquidia Corporation LQDA Open Liquidia Corporation in new tab

37.68 USD
EPS
-0.80
P/B
68.58
ROE
-111.06
Beta
0.56
Target Price
50.67 USD
Liquidia Corporation logo

Liquidia Corporation

🧾 Earnings Recap – Q3 2025

Liquidia Corporation achieved a significant operational breakthrough in Q3 2025, with YUTREPIA generating $51.7 million in net sales during its first full quarter post-launch, positioning the company ahead of profitability expectations.

  • YUTREPIA received over 2,000 unique prescriptions and initiated therapy for more than 1,500 patients within its first full quarter.
  • Positive adjusted EBITDA of $10.1 million marked a faster path to profitability than anticipated, with net cash flow becoming positive for the first month in September.
  • Approximately 75% of YUTREPIA patients are new to treprostinil, indicating strong market penetration and physician acceptance.
  • Liquidia plans to expand YUTREPIA's clinical utility via open-label studies and research into other potential indications like IPF and PPF.
  • Company's cash position strengthened with $157.5 million on hand, allowing for continued investment in innovation.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 7, 2026
EPS-0.80
Book Value0.51
Price to Book68.58
Debt/Equity442.32
% Insiders13.398%
Growth
Revenue Growth30.55%
Estimates
Forward P/E6.72
Forward EPS5.24
Target Mean Price50.67

DCF Valuation

Tweak assumptions to recompute fair value for Liquidia Corporation (LQDA)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Liquidia Corporation Logo Liquidia Corporation Analysis (LQDA)

United States Health Care Official Website Stock

Is Liquidia Corporation a good investment? Liquidia Corporation (LQDA) is currently trading at 37.68 USD. Market analysts have a consensus price target of 50.67 USD. This suggests a potential upside from current levels.

Earnings Schedule: Liquidia Corporation is expected to release its next earnings report on May 7, 2026. The market consensus estimate for Forward EPS is 5.24.

Investor FAQ

Does Liquidia Corporation pay a dividend?

No, it does not currently pay a dividend.

What asset class is Liquidia Corporation?

Liquidia Corporation is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 7, 2026. The company currently has a trailing EPS of -0.80.

Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Exchange Ticker
NMS (United States) LQDA

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion